|Videos|November 28, 2017

What is the Role of the Clinical Laboratory in Outbreak Response?

Daniel Diekema, MD, discusses the different roles that clinical laboratories play in outbreak response.

Daniel Diekema, MD, professor of Infectious Diseases at the University of Iowa, discusses the different roles that clinical laboratories play in outbreak response.

Interview Transcript (modified slightly for readability):

“The lab has a lot of roles to play in outbreak response. The first one is detecting the outbreak in the first place. So, early detection really requires the laboratory to be alert to the isolation of the same organism on the same unit during the same period of time, for example. So, detection of the outbreak.

Then, during an investigation of the outbreak, the lab roles include additional case findings, going back to determine if other cases have occurred that haven’t yet been recognized. And then the lab plays essential roles in outbreak investigation—where did the organism come from? How is it being spread? The lab can offer things like molecular typing or whole genome sequencing as part of the lab’s investigation.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.